PD-L1 upregulation was JAK2/STAT1-dependent in head and neck cancer with wild-type EGFR, whereas JAK2 inhibition resulted in both basal and EGF-mediated downregulation of PD-L1. Here, CD274 is linked to head and neck cancer.